$PPCBJul 21, 2026, 8:30 AM ETAI processed
Propanc publishes peer‐reviewed study showing scalable production of recombinant rec‐PRP proenzymes
AI Summary
Propanc reported a peer‐reviewed publication showing scalable recombinant production of trypsinogen and chymotrypsinogen (rec‐PRP) in Komagataella phaffii with stable purified proteins using co‐expression of HAC1 and PDI1. The company plans small‐scale, non‐GMP production of rec‐PRP to test compatibility with its bovine‐derived lead PRP (which targets a Phase 1b first‐in‐human study in advanced solid tumors in early 2027) and highlights potential advantages like crystallized product stability for distribution without refrigeration.
Positives
- Peer‑reviewed paper reports scalable recombinant production and stable purification of both proenzymes in K. phaffii
- rec‑PRP is being developed as a synthetic backup/follow‑on to the lead bovine‑derived PRP candidate
- Company highlights potential product benefits (crystallized proteins, longer shelf life, less need for refrigeration) that could ease global distribution
Negatives
- Current rec‑PRP production is small‑scale and non‑GMP, not yet suitable for clinical use
- No clinical efficacy or safety data reported for rec‑PRP; PRP Phase 1b remains planned for early 2027
- Regulatory pathway for rec‑PRP has not been determined